1
|
López-Vicario C, Rius B, Alcaraz-Quiles J, González-Périz A, Martínez-Puchol AI, Casulleras M, Duran-Güell M, Ibarzabal A, Corcelles R, Laguna-Fernández A, Back M, Titos E, Clària J. Association of a variant in the gene encoding for ERV1/ChemR23 with reduced inflammation in visceral adipose tissue from morbidly obese individuals. Sci Rep 2017; 7:15724. [PMID: 29146976 PMCID: PMC5691181 DOI: 10.1038/s41598-017-15951-z] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2017] [Accepted: 11/03/2017] [Indexed: 12/31/2022] Open
Abstract
Obesity comorbidities are closely associated with chronic low-grade adipose tissue inflammation. A number of SNPs associated with inflammation has been identified, underscoring the impact of genetic determinants on this process. Here, we screened SNPs in genes with pro-inflammatory (IL-1β, IL-6, STAT3 and JAK2), anti-inflammatory (IL-10 and SOCS3) and pro-resolving (ERV1/ChemR23) properties in 101 obese and 99 non-obese individuals. Among the SNPs analyzed, we identified that individuals carrying a C allele in the rs1878022 polymorphism of the ERV1/ChemR23 gene, which encodes for the receptor of the pro-resolving mediator RvE1, had increased ERV1/ChemR23 protein expression and reduced levels of the inflammatory cytokine IL-6 in adipose tissue. Moreover, patients carrying the C allele in homozygosity had lower plasma levels of IL-6, IFN-α2, IL-15, IL-1ra, IL-10, GM-CSF, G-CSF and VEGF and enhanced leukocyte responsiveness to RvE1. C-carriers also exhibited decreased TAG to HDL ratio, a surrogate marker of insulin resistance and a predictor of incident fatty liver. Finally, we confirmed in vivo that the ERV1/ChemR23 receptor regulates systemic and tissue inflammation since mice lacking ERV1/ChemR23 expression showed increased IL-6 levels in adipose tissue and peritoneal macrophages. Together, our study identified an ERV1/ChemR23 variant that protects patients with obesity from excessive inflammatory burden.
Collapse
Affiliation(s)
- Cristina López-Vicario
- Department of Biochemistry and Molecular Genetics, Hospital Clínic, IDIBAPS, Barcelona, Spain. .,CIBERehd, University of Barcelona, Barcelona, Spain.
| | - Bibiana Rius
- Department of Biochemistry and Molecular Genetics, Hospital Clínic, IDIBAPS, Barcelona, Spain
| | - José Alcaraz-Quiles
- Department of Biochemistry and Molecular Genetics, Hospital Clínic, IDIBAPS, Barcelona, Spain
| | - Ana González-Périz
- Department of Biochemistry and Molecular Genetics, Hospital Clínic, IDIBAPS, Barcelona, Spain
| | | | - Mireia Casulleras
- Department of Biochemistry and Molecular Genetics, Hospital Clínic, IDIBAPS, Barcelona, Spain
| | - Marta Duran-Güell
- Department of Biochemistry and Molecular Genetics, Hospital Clínic, IDIBAPS, Barcelona, Spain
| | - Ainitze Ibarzabal
- Department of Gastrointestinal Surgery, Hospital Clínic, IDIBAPS, Barcelona, Spain
| | - Ricard Corcelles
- Department of Gastrointestinal Surgery, Hospital Clínic, IDIBAPS, Barcelona, Spain
| | - Andrés Laguna-Fernández
- Centre for Molecular Medicine, Department of Medicine, Karolinska Institutet and Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden
| | - Magnus Back
- Centre for Molecular Medicine, Department of Medicine, Karolinska Institutet and Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden
| | - Esther Titos
- Department of Biochemistry and Molecular Genetics, Hospital Clínic, IDIBAPS, Barcelona, Spain.,CIBERehd, University of Barcelona, Barcelona, Spain
| | - Joan Clària
- Department of Biochemistry and Molecular Genetics, Hospital Clínic, IDIBAPS, Barcelona, Spain. .,CIBERehd, University of Barcelona, Barcelona, Spain. .,Department of Biomedical Sciences, University of Barcelona, Barcelona, Spain.
| |
Collapse
|
2
|
Petri MH, Laguna-Fernández A, Gonzalez-Diez M, Paulsson-Berne G, Hansson GK, Bäck M. The role of the FPR2/ALX receptor in atherosclerosis development and plaque stability. Cardiovasc Res 2014; 105:65-74. [PMID: 25341894 PMCID: PMC4277257 DOI: 10.1093/cvr/cvu224] [Citation(s) in RCA: 90] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
Abstract
AIMS The formyl peptide receptor (FPR) subtype FPR2/ALX transduces pro-inflammatory responses and participates in the resolution of inflammation depending on activation. The aim of the present study was to unravel the role of FPR2/ALX signalling in atherosclerosis. METHODS AND RESULTS Expression of FPR2/ALX was analysed in 127 human carotid atherosclerotic lesions and revealed that this receptor was expressed on macrophages, smooth muscle cells (SMCs), and endothelial cells. Furthermore, FPR2/ALX mRNA levels were significantly up-regulated in atherosclerotic lesions compared with healthy vessels. In multiple regression, age, creatinine, and clinical signs of increased cerebral ischaemia were independent predictors of FPR2/ALX expression. To provide mechanistic insights into these observations, we generated Ldlr(-/-)xFpr2(-/-) mice, which exhibited delayed atherosclerosis development and less macrophage infiltration compared with Ldlr(-/-)xFpr2(+/+) mice. These findings were reproduced by transplantation of Fpr2(-/-) bone marrow into Ldlr(-/-) mice and further extended by in vitro experiments, demonstrating a lower inflammatory state in Fpr2(-/-) macrophages. FPR2/ALX expression correlated with chemo- and cytokines in human atherosclerotic lesions and leucocytes. Finally, atherosclerotic lesions in Ldlr(-/-)xFpr2(-/-) mice exhibited decreased collagen content, and Fpr2(-/-) SMCs exhibited a profile of increased collagenase and decreased collagen production pathways. CONCLUSION FPR2/ALX is proatherogenic due to effects on bone marrow-derived cells, but promoted a more stable plaque phenotype through effects on SMCs. Taken together, these results suggest a dual role of FPR2/ALX signalling in atherosclerosis by way of promoting disease progression and but increasing plaque stability.
Collapse
Affiliation(s)
- Marcelo H Petri
- Experimental Cardiovascular Research Unit, Karolinska Institutet, Center for Molecular Medicine, L8: 03, Karolinska University Hospital, Stockholm 171 76, Sweden
| | - Andrés Laguna-Fernández
- Experimental Cardiovascular Research Unit, Karolinska Institutet, Center for Molecular Medicine, L8: 03, Karolinska University Hospital, Stockholm 171 76, Sweden
| | - Maria Gonzalez-Diez
- Atherosclerosis Research Unit, Center for Molecular Medicine, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
| | - Gabrielle Paulsson-Berne
- Experimental Cardiovascular Research Unit, Karolinska Institutet, Center for Molecular Medicine, L8: 03, Karolinska University Hospital, Stockholm 171 76, Sweden
| | - Göran K Hansson
- Experimental Cardiovascular Research Unit, Karolinska Institutet, Center for Molecular Medicine, L8: 03, Karolinska University Hospital, Stockholm 171 76, Sweden
| | - Magnus Bäck
- Experimental Cardiovascular Research Unit, Karolinska Institutet, Center for Molecular Medicine, L8: 03, Karolinska University Hospital, Stockholm 171 76, Sweden Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden
| |
Collapse
|
3
|
Pineda B, Serna E, Laguna-Fernández A, Noguera I, Panach L, Hermenegildo C, Tarín JJ, Cano A, García-Pérez MÁ. Gene expression profile induced by ovariectomy in bone marrow of mice: a functional approach to identify new candidate genes associated to osteoporosis risk in women. Bone 2014; 65:33-41. [PMID: 24815918 DOI: 10.1016/j.bone.2014.05.001] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/04/2013] [Revised: 04/16/2014] [Accepted: 05/01/2014] [Indexed: 01/24/2023]
Abstract
Osteoporosis is a multifactorial skeletal pathology with a main genetic component. To date, however, the majority of genes associated with this pathology remain unknown since genes cataloged to date only explain a part of the heritability of bone phenotypes. In the present study, we have used a genome-wide gene expression approach by means of microarrays to identify new candidate genes involved in the physiopathology of osteoporosis, using as a model the ovariectomized (OVX) mice by comparing global bone marrow gene expression of the OVX mice with those of SHAM operated mice. One hundred and eighty transcripts were found to be differentially expressed between groups. The analysis showed 23 significant regulatory networks, of which the top five canonical pathways included B-cell development, primary immunodeficiency signaling, PI3K signaling in B-cells, phospholipase C signaling, and FcgRIIB signaling in B-cells. Twelve differentially expressed genes were validated by MALDI-TOF mass spectrometry with good reproducibility. Finally, the association to bone phenotypes of SNPs in genes whose expression was increased (IL7R and CD79A) or decreased (GPX3 and IRAK3) by OVX in mice was analyzed in a cohort of 706 postmenopausal women. We detected an association of a SNP in a gene involved in the detoxification of free radicals like glutathione peroxidase 3 (GPX3) with femoral neck BMD (rs8177447, P=0.043) and two SNPs in the Ig-alpha protein of the B-cell antigen component gene (CD79A) with lumbar spine BMD (rs3810153 and rs1428922, P=0.016 and P=0.001, respectively). These results reinforce the role of antioxidant pathways and of B-cells in bone metabolism. Furthermore, it shows that a genome-wide gene expression approach in animal models is a useful method for detecting genes associated to BMD and osteoporosis risk in humans.
Collapse
Affiliation(s)
- Begoña Pineda
- Research Foundation, Institute of Health Research INCLIVA, Valencia, Spain
| | - Eva Serna
- Research Unit - INCLIVA, Faculty of Medicine, University of Valencia, Spain
| | | | - Inmaculada Noguera
- Research Unit - INCLIVA, Faculty of Medicine, University of Valencia, Spain
| | - Layla Panach
- Research Foundation, Institute of Health Research INCLIVA, Valencia, Spain
| | - Carlos Hermenegildo
- Research Foundation, Institute of Health Research INCLIVA, Valencia, Spain; Department of Physiology, University of Valencia, Spain
| | - Juan J Tarín
- Department of Functional Biology and Physical Anthropology, University of Valencia, Spain
| | - Antonio Cano
- Department of Pediatrics, Obstetrics and Gynecology, University of Valencia, Spain
| | - Miguel Ángel García-Pérez
- Research Foundation, Institute of Health Research INCLIVA, Valencia, Spain; Department of Genetics, University of Valencia, Spain.
| |
Collapse
|
4
|
Novella S, Laguna-Fernández A, Lázaro-Franco M, Sobrino A, Bueno-Betí C, Tarín JJ, Monsalve E, Sanchís J, Hermenegildo C. Estradiol, acting through estrogen receptor alpha, restores dimethylarginine dimethylaminohydrolase activity and nitric oxide production in oxLDL-treated human arterial endothelial cells. Mol Cell Endocrinol 2013; 365:11-6. [PMID: 22982060 DOI: 10.1016/j.mce.2012.08.020] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/29/2011] [Revised: 08/28/2012] [Accepted: 08/29/2012] [Indexed: 10/27/2022]
Abstract
Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide (NO) synthase. ADMA accumulation, mainly due to a decreased dimethylarginine dimethylaminohydrolase (DDAH) activity, has been related to the development of cardiovascular diseases. We investigate whether estradiol prevents the changes induced by oxidized low density lipoprotein (oxLDL) on the DDAH/ADMA/NO pathway in human umbilical artery endothelial cells (HUAEC). HUAEC were exposed to estradiol, native LDL (nLDL), oxLDL and their combinations for 24 h. In some experiments, cells were also exposed to the unspecific estrogen receptor (ER) antagonist ICI 182780, the specific ERα antagonist MPP or specific agonists for ERα, ERβ and GPER. ADMA concentration was measured by HPLC and concentration of NO by amperometry. Protein expression and DDAH activity were measured by immunoblotting and an enzymatic method, respectively. oxLDL, but not nLDL, increased ADMA concentration with a concomitant decrease on DDAH activity. oxLDL reduced eNOS protein and NO production. Estradiol alone had no effects on DDAH/ADMA/NO pathway, but increased the attenuated endothelial NO production induced by oxLDL by reduction in ADMA and preventing loss of eNOS protein levels. ICI 182780 and MPP completely abolished these effects of estradiol on oxLDL-exposed cells. ERα agonist, but not ERβ and GPER agonists, mirrored estradiol effects on NO production. In conclusion, estradiol restores (1) DDAH activity, and therefore ADMA levels, and (2) NO production impaired by oxLDL in HUAEC acting through ERα.
Collapse
MESH Headings
- Amidohydrolases/antagonists & inhibitors
- Amidohydrolases/chemistry
- Amidohydrolases/metabolism
- Arginine/adverse effects
- Arginine/analogs & derivatives
- Arginine/antagonists & inhibitors
- Arginine/metabolism
- Blotting, Western
- Cells, Cultured
- Endothelium, Vascular/cytology
- Endothelium, Vascular/drug effects
- Endothelium, Vascular/metabolism
- Estradiol/agonists
- Estradiol/chemistry
- Estradiol/metabolism
- Estrogen Antagonists/pharmacology
- Estrogen Receptor alpha/agonists
- Estrogen Receptor alpha/antagonists & inhibitors
- Estrogen Receptor alpha/metabolism
- Estrogen Receptor beta/agonists
- Estrogen Receptor beta/antagonists & inhibitors
- Estrogen Receptor beta/metabolism
- Estrogens, Non-Steroidal/pharmacology
- Humans
- Isoenzymes/antagonists & inhibitors
- Isoenzymes/chemistry
- Isoenzymes/metabolism
- Lipoproteins, LDL/adverse effects
- Lipoproteins, LDL/antagonists & inhibitors
- Nitric Oxide/agonists
- Nitric Oxide/antagonists & inhibitors
- Nitric Oxide/metabolism
- Nitric Oxide Synthase Type III/antagonists & inhibitors
- Nitric Oxide Synthase Type III/chemistry
- Nitric Oxide Synthase Type III/metabolism
- Protein Stability
- Protein-Arginine N-Methyltransferases/metabolism
- Receptors, Estrogen/agonists
- Receptors, Estrogen/antagonists & inhibitors
- Receptors, Estrogen/metabolism
- Receptors, G-Protein-Coupled/agonists
- Receptors, G-Protein-Coupled/antagonists & inhibitors
- Receptors, G-Protein-Coupled/metabolism
- Repressor Proteins/metabolism
- Umbilical Arteries/cytology
Collapse
Affiliation(s)
- Susana Novella
- Research Foundation, Hospital Clínico of Valencia - INCLIVA, Valencia, Spain.
| | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Hermenegildo C, Sobrino A, Monsalve E, Bueno-Betí C, Laguna-Fernández A, Sánchez-Ferrer CF, Peiró C, Novella S. ESTRADIOL-INDUCED NITRIC OXIDE PRODUCTION AND VASCULAR RELAXATION ARE MEDIATED THROUGH ANGIOTENSIN 1-7 MAS RECEPTOR. J Hypertens 2011. [DOI: 10.1097/00004872-201106001-00157] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|